Fluorescence tools to identify Novel SERCA activators

University of Minnesota Ph.D. dissertation. August 2013. Major: Biochemistry, Molecular Bio, and Biophysics. Advisor: David D. Thomas. 1 computer file (PDF); x, 121 pages.

[1]  David D. Thomas,et al.  Phospholamban structural dynamics in lipid bilayers probed by a spin label rigidly coupled to the peptide backbone. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D. Belke,et al.  Altered cardiac calcium handling in diabetes , 2004, Current hypertension reports.

[3]  T. Squier,et al.  Conformational changes within the cytosolic portion of phospholamban upon release of Ca-ATPase inhibition. , 2004, Biochemistry.

[4]  R. Hajjar,et al.  Mechanoelectrical remodeling and arrhythmias during progression of hypertrophy , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Y. Sugita,et al.  Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  I. V. Negrashov,et al.  Direct detection of phospholamban and sarcoplasmic reticulum Ca-ATPase interaction in membranes using fluorescence resonance energy transfer. , 2004, Biochemistry.

[7]  R. Kovacs,et al.  Phospholamban forms Ca2+-selective channels in lipid bilayers. , 1988, The Journal of biological chemistry.

[8]  J. Andersen.  Functional consequences of alterations to amino acids at the M5S5 boundary of the Ca(2+)-ATPase of sarcoplasmic reticulum. Mutation Tyr763-->Gly uncouples ATP hydrolysis from Ca2+ transport. , 1995, The Journal of biological chemistry.

[9]  J. Guerrero,et al.  Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Tracy J. Pritchard,et al.  The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase. , 2012, Journal of molecular and cellular cardiology.

[11]  G. Dorn,et al.  A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Lompré,et al.  Effect of cyclopiazonic acid, an inhibitor of the sarcoplasmic reticulum Ca-ATPase, on skeletal muscles from normal and mdx mice. , 2005, Acta physiologica Scandinavica.

[13]  R. Hajjar,et al.  Modulation of Cardiac Contractility by the Phopholamban/SERCA2a Regulatome , 2012, Circulation research.

[14]  M. Chalfie.  GREEN FLUORESCENT PROTEIN , 1995, Photochemistry and photobiology.

[15]  F. G. Prendergast,et al.  Biophysics of the green fluorescent protein. , 1999, Methods in cell biology.

[16]  D. Bers.  Cardiac excitation–contraction coupling , 2002, Nature.

[17]  L. Jones,et al.  Characterizing Phospholamban to Sarco(endo)plasmic Reticulum Ca2+-ATPase 2a (SERCA2a) Protein Binding Interactions in Human Cardiac Sarcoplasmic Reticulum Vesicles Using Chemical Cross-linking* , 2012, The Journal of Biological Chemistry.

[18]  Andrea H. Brand,et al.  Imaging into the future: visualizing gene expression and protein interactions with fluorescent proteins , 2002, Nature Cell Biology.

[19]  A. Pastore,et al.  The importance of serine 776 in Ataxin-1 partner selection: A FRET Analysis , 2012, Scientific Reports.

[20]  K. Campbell,et al.  Förster Transfer Recovery Reveals That Phospholamban Exchanges Slowly From Pentamers but Rapidly From the SERCA Regulatory Complex , 2007, Circulation Research.

[21]  U. Schmidt,et al.  Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. , 1999, Circulation.

[22]  R. Bobe,et al.  Multiple and diverse coexpression, location, and regulation of additional SERCA2 and SERCA3 isoforms in nonfailing and failing human heart. , 2010, Journal of molecular and cellular cardiology.

[23]  S. Negash,et al.  Phospholamban remains associated with the Ca2+- and Mg2+-dependent ATPase following phosphorylation by cAMP-dependent protein kinase. , 2000, The Biochemical journal.

[24]  C. Toyoshima,et al.  Concerted conformational effects of Ca2+ and ATP are required for activation of sequential reactions in the Ca2+ ATPase (SERCA) catalytic cycle. , 2006, Biochemistry.

[25]  Y. Sugita,et al.  Crystal Structures of Ca2+‐ATPase in Various Physiological States , 2003, Annals of the New York Academy of Sciences.

[26]  H. Orr,et al.  Spinocerebellar Ataxia Type 1—Modeling the Pathogenesis of a Polyglutamine Neurodegenerative Disorder in Transgenic Mice , 2000, Journal of neuropathology and experimental neurology.

[27]  D. D. Thomas,et al.  Effects of Ser16 phosphorylation on the allosteric transitions of phospholamban/Ca(2+)-ATPase complex. , 2006, Journal of molecular biology.

[28]  Swati Tyagi,et al.  Click strategies for single-molecule protein fluorescence. , 2012, Journal of the American Chemical Society.

[29]  L. Janssen,et al.  The NADPH oxidase inhibitor diphenyleneiodonium is also a potent inhibitor of cholinesterases and the internal Ca2+ pump , 2009, British journal of pharmacology.

[30]  D. Maclennan,et al.  Functional consequences of alterations to Gly310, Gly770, and Gly801 located in the transmembrane domain of the Ca(2+)-ATPase of sarcoplasmic reticulum. , 1992, The Journal of biological chemistry.

[31]  Anuradha Kalyanasundaram,et al.  SERCA pump isoforms: Their role in calcium transport and disease , 2007, Muscle & nerve.

[32]  Bengt Svensson,et al.  Interdomain fluorescence resonance energy transfer in SERCA probed by cyan-fluorescent protein fused to the actuator domain. , 2008, Biochemistry.

[33]  P. Vangheluwe,et al.  Distinct Roles of the C-terminal 11th Transmembrane Helix and Luminal Extension in the Partial Reactions Determining the High Ca2+ Affinity of Sarco(endo)plasmic Reticulum Ca2+-ATPase Isoform 2b (SERCA2b)* , 2012, The Journal of Biological Chemistry.

[34]  R. Hajjar,et al.  Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. , 2009, Journal of molecular and cellular cardiology.

[35]  E. Lemke.  Site-specific labeling of proteins for single-molecule FRET measurements using genetically encoded ketone functionalities. , 2011, Methods in molecular biology.

[36]  M. E. Kargacin,et al.  The sarcoplasmic reticulum calcium pump is functionally altered in dystrophic muscle. , 1996, Biochimica et biophysica acta.

[37]  D. Bers,et al.  Phospholamban Oligomerization, Quaternary Structure, and Sarco(endo)plasmic Reticulum Calcium ATPase Binding Measured by Fluorescence Resonance Energy Transfer in Living Cells* , 2008, Journal of Biological Chemistry.

[38]  David H. MacLennan,et al.  Structural biology: Pumping ions , 2000, Nature.

[39]  P. O’Campo,et al.  Moving from rhetoric to reality: adapting Housing First for homeless individuals with mental illness from ethno-racial groups , 2012, BMC Health Services Research.

[40]  David D. Thomas,et al.  Phospholamban mutants compete with wild type for SERCA binding in living cells. , 2012, Biochemical and biophysical research communications.

[41]  I. V. Negrashov,et al.  Structural dynamics of the myosin relay helix by time-resolved EPR and FRET , 2009, Proceedings of the National Academy of Sciences.

[42]  D. Cox,et al.  Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure , 2011, Science.

[43]  W. Huckle,et al.  Characterization and quantitation of phospholamban and its phosphorylation state using antibodies. , 2000, Biochemical and biophysical research communications.

[44]  D. Dobrota,et al.  Age-associated changes in Ca(2+)-ATPase and oxidative damage in sarcoplasmic reticulum of rat heart. , 2012, Physiological research.

[45]  D. D. Thomas,et al.  Conformational transitions in the calcium adenosinetriphosphatase studied by time-resolved fluorescence resonance energy transfer. , 1989, Biochemistry.

[46]  K. Mikoshiba,et al.  Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. , 1995, Circulation.

[47]  K. Chien,et al.  Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals. , 2007, Journal of the American College of Cardiology.

[48]  G. Hasenfuss,et al.  Cardiac inotropes: current agents and future directions. , 2011, European heart journal.

[49]  E. Leberer,et al.  Functional consequences of mutations in the beta-strand sector of the Ca2(+)-ATPase of sarcoplasmic reticulum. , 1989, The Journal of biological chemistry.

[50]  Y. Sagara,et al.  Comparative studies of cardiac and skeletal sarcoplasmic reticulum ATPases. Effect of a phospholamban antibody on enzyme activation by Ca2+. , 1993, The Journal of biological chemistry.

[51]  R. Xiao,et al.  Dual site phospholamban phosphorylation and its physiological relevance in the heart. , 2002, Trends in cardiovascular medicine.

[52]  Kay E. Davies,et al.  Hsp72 preserves muscle function and slows progression of severe muscular dystrophy , 2012, Nature.

[53]  D. Maclennan,et al.  Scanning Mutagenesis Reveals a Similar Pattern of Mutation Sensitivity in Transmembrane Sequences M4, M5, and M6, but Not in M8, of the Ca2+-ATPase of Sarcoplasmic Reticulum (SERCA1a)* , 1996, The Journal of Biological Chemistry.

[54]  D. Stokes,et al.  Cross-linking of C-terminal Residues of Phospholamban to the Ca2+ Pump of Cardiac Sarcoplasmic Reticulum to Probe Spatial and Functional Interactions within the Transmembrane Domain* , 2006, Journal of Biological Chemistry.

[55]  C. Toyoshima,et al.  Calcium transport by sarcoplasmic reticulum Ca(2+)-ATPase. Role of the A domain and its C-terminal link with the transmembrane region. , 2002, The Journal of biological chemistry.

[56]  J. East,et al.  A diversity of SERCA Ca2+ pump inhibitors. , 2011, Biochemical Society transactions.

[57]  S. Park,et al.  Sarco(endo)plasmic reticulum Ca2+-ATPase 2b is a major regulator of endoplasmic reticulum stress and glucose homeostasis in obesity , 2010, Proceedings of the National Academy of Sciences.

[58]  David D. Thomas,et al.  Insulin-dependent rescue from cardiogenic shock is not mediated by phospholamban phosphorylation , 2009, Clinical toxicology.

[59]  Sanjiv J. Shah,et al.  Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORI , 2009, American heart journal.

[60]  David D. Thomas,et al.  Oligomeric Interactions of Sarcolipin and the Ca-ATPase* , 2011, The Journal of Biological Chemistry.

[61]  D. Ferrington,et al.  Comparable levels of Ca-ATPase inhibition by phospholamban in slow-twitch skeletal and cardiac sarcoplasmic reticulum. , 2002, Biochemistry.

[62]  L. Jones,et al.  Phospholamban: protein structure, mechanism of action, and role in cardiac function. , 1998, Physiological reviews.

[63]  David D. Thomas,et al.  New and Notable Rotational Diffusion of Membrane Proteins: Characterization of Protein- Protein Interactions in Membranes Protein-protein Interactions in Calcium Transport Regulation Probed by Saturation Transfer Electron Paramagnetic Resonance , 2022 .

[64]  Tuning the structural coupling between the transmembrane and cytoplasmic domains of phospholamban to control sarcoplasmic reticulum Ca2+-ATPase (SERCA) function , 2012, Journal of Muscle Research and Cell Motility.

[65]  H. Ceulemans,et al.  Structural basis for the high Ca2+ affinity of the ubiquitous SERCA2b Ca2+ pump , 2009, Proceedings of the National Academy of Sciences.

[66]  H. Krum,et al.  Novel therapies in acute and chronic heart failure. , 2012, Pharmacology & therapeutics.

[67]  D. Bers,et al.  Calcium and cardiomyopathies. , 2007, Sub-cellular biochemistry.

[68]  J. Chrast,et al.  Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. , 2004, The Journal of clinical investigation.

[69]  David D. Thomas,et al.  Phosphorylation-dependent conformational switch in spin-labeled phospholamban bound to SERCA. , 2006, Journal of molecular biology.

[70]  R. Schwinger,et al.  Modulation of SERCA: implications for the failing human heart , 2002, Basic Research in Cardiology.

[71]  B. Vilsen,et al.  Structure‐function relationships of cation translocation by Ca2+‐ and Na+,K+‐ATPases studied by site‐directed mutagenesis , 1995 .

[72]  A. Hovnanian.  SERCA pumps and human diseases. , 2007, Sub-cellular biochemistry.

[73]  Masahiko Hoshijima,et al.  Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery , 2002, Nature Medicine.

[74]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[75]  M. Gheorghiade,et al.  Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. , 2011, Discovery medicine.

[76]  J. Feher,et al.  Determinants of calcium loading at steady state in sarcoplasmic reticulum. , 1983, Biochimica et biophysica acta.

[77]  R. Hajjar,et al.  Calcium Cycling Proteins and Their Association With Heart Failure , 2011, Clinical pharmacology and therapeutics.

[78]  L. Monserrat,et al.  Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN –42 C>G mutation , 2007, European journal of heart failure.

[79]  I. Jóna,et al.  Modulation of Sarcoplasmic Reticulum Function by Na+/K+ Pump Inhibitors with Different Toxicity: Digoxin and PST2744 [(E,Z)-3-((2-Aminoethoxy)imino)androstane-6,17-dione Hydrochloride] , 2005, Journal of Pharmacology and Experimental Therapeutics.

[80]  D. Bylund.  Alpha- and beta-adrenergic receptors: Ahlquist's landmark hypothesis of a single mediator with two receptors. , 2007, American journal of physiology. Endocrinology and metabolism.

[81]  J. H. Collins,et al.  Sequence analysis of phospholamban. Identification of phosphorylation sites and two major structural domains. , 1986, The Journal of biological chemistry.

[82]  P. Nissen,et al.  In and out of the cation pumps: P-type ATPase structure revisited. , 2010, Current opinion in structural biology.

[83]  A. Hovnanian,et al.  Calcium pumps and keratinocytes: lessons from Darier's disease and Hailey–Hailey disease , 2004, The British journal of dermatology.

[84]  A. Ting,et al.  Imaging protein-protein interactions inside living cells via interaction-dependent fluorophore ligation. , 2011, Journal of the American Chemical Society.

[85]  R. Matsuoka,et al.  Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. , 2003, Biochemical and biophysical research communications.

[86]  M. Nakasako,et al.  Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 Å resolution , 2000, Nature.

[87]  G. Bianchi,et al.  Pharmacological Profile of the Novel Inotropic Agent (E,Z)-3-((2-Aminoethoxy)imino)androstane-6,17-dione Hydrochloride (PST2744) , 2002, Journal of Pharmacology and Experimental Therapeutics.

[88]  Poul Nissen,et al.  Transport mechanism of the sarcoplasmic reticulum Ca2+ -ATPase pump. , 2005, Current opinion in structural biology.

[89]  Jiqiu Chen,et al.  High-Throughput FRET Assay Yields Allosteric SERCA Activators , 2013, Journal of biomolecular screening.

[90]  David D. Thomas,et al.  Controlling the Inhibition of the Sarcoplasmic Ca2+-ATPase by Tuning Phospholamban Structural Dynamics* , 2007, Journal of Biological Chemistry.

[91]  David D. Thomas,et al.  On the function of pentameric phospholamban: ion channel or storage form? , 2009, Biophysical journal.

[92]  G. Veglia,et al.  Structural topology of phospholamban pentamer in lipid bilayers by a hybrid solution and solid-state NMR method , 2011, Proceedings of the National Academy of Sciences.

[93]  J. Mariani,et al.  Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals , 2008, Gene Therapy.

[94]  David D. Thomas,et al.  The alpha-helical propensity of the cytoplasmic domain of phospholamban: a molecular dynamics simulation of the effect of phosphorylation and mutation. , 2005, Biophysical journal.

[95]  J. Chou,et al.  The structure of phospholamban pentamer reveals a channel-like architecture in membranes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[96]  D. Maclennan,et al.  Phospholamban Domain Ib Mutations Influence Functional Interactions with the Ca2+-ATPase Isoform of Cardiac Sarcoplasmic Reticulum* , 1998, The Journal of Biological Chemistry.

[97]  Harvard Medical School,et al.  Targeting Phospholamban by Gene Transfer in Human Heart Failure , 2002, Circulation.

[98]  H. Ly,et al.  AAV9.I-1c Delivered via Direct Coronary Infusion in a Porcine Model of Heart Failure Improves Contractility and Mitigates Adverse Remodeling , 2013, Circulation. Heart failure.

[99]  P. Vangheluwe,et al.  Modulating sarco(endo)plasmic reticulum Ca2+ ATPase 2 (SERCA2) activity: cell biological implications. , 2005, Cell calcium.

[100]  D. Maclennan,et al.  Mutation of aspartic acid-351, lysine-352, and lysine-515 alters the Ca2+ transport activity of the Ca2+-ATPase expressed in COS-1 cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[101]  M. Ikura,et al.  Characterization of the ATP-binding domain of the sarco(endo)plasmic reticulum Ca(2+)-ATPase: probing nucleotide binding by multidimensional NMR. , 2002, Biochemistry.

[102]  R. Hajjar,et al.  Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. , 2011, Journal of molecular and cellular cardiology.

[103]  P. Gélébart,et al.  Identification of a new SERCA2 splice variant regulated during monocytic differentiation. , 2003, Biochemical and biophysical research communications.

[104]  D. D. Thomas,et al.  Synthetic null-cysteine phospholamban analogue and the corresponding transmembrane domain inhibit the Ca-ATPase. , 2000, Biochemistry.

[105]  P. Nissen,et al.  The sarcoplasmic Ca2+-ATPase: design of a perfect chemi-osmotic pump , 2010, Quarterly Reviews of Biophysics.

[106]  R. Hajjar,et al.  Expression of active protein phosphatase 1 inhibitor-1 attenuates chronic beta-agonist-induced cardiac apoptosis , 2010, Basic Research in Cardiology.

[107]  Z. Chen,et al.  Reexamination of the Role of the Leucine/Isoleucine Zipper Residues of Phospholamban in Inhibition of the Ca2+ Pump of Cardiac Sarcoplasmic Reticulum* , 2000, The Journal of Biological Chemistry.

[108]  J. Fujii,et al.  Molecular structure and function of phospholamban: the regulatory protein of calcium pump in cardiac sarcoplasmic reticulum. , 1989, Advances in experimental medicine and biology.

[109]  D. Maclennan,et al.  Physical Interactions between Phospholamban and Sarco(endo)plasmic Reticulum Ca2+-ATPases Are Dissociated by Elevated Ca2+, but Not by Phospholamban Phosphorylation, Vanadate, or Thapsigargin, and Are Enhanced by ATP* , 2000, The Journal of Biological Chemistry.

[110]  J. Cleveland,et al.  Human SERCA2a levels correlate inversely with age in senescent human myocardium. , 1998, Journal of the American College of Cardiology.

[111]  Alexander Kyrychenko,et al.  High-performance time-resolved fluorescence by direct waveform recording. , 2010, The Review of scientific instruments.

[112]  Y. Mou,et al.  rAAV‐asPLB transfer attenuates abnormal sarcoplasmic reticulum Ca2+‐ATPase activity and cardiac dysfunction in rats with myocardial infarction , 2008, European journal of heart failure.

[113]  A. Datta,et al.  Proteoliposome as the model for the study of membrane-bound enzymes and transport proteins , 2004, Molecular and Cellular Biochemistry.

[114]  Robert G. Johnson.  Pharmacology of the Cardiac Sarcoplasmic Reticulum Calcium ATPase‐Phospholamban Interaction , 1998, Annals of the New York Academy of Sciences.

[115]  G. Dorn,et al.  Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. , 2003, The Journal of clinical investigation.

[116]  W. Kühlbrandt.  Biology, structure and mechanism of P-type ATPases , 2004, Nature Reviews Molecular Cell Biology.

[117]  Virginia W Cornish,et al.  Chemical tags: Applications in live cell fluorescence imaging , 2011, Journal of biophotonics.

[118]  G. Filippatos,et al.  Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na–K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? , 2009, Heart Failure Reviews.

[119]  David D. Thomas,et al.  Structural and functional dynamics of an integral membrane protein complex modulated by lipid headgroup charge. , 2012, Journal of molecular biology.

[120]  P. Gélébart,et al.  Endoplasmic reticulum calcium pumps and cancer. , 2011, BioFactors.

[121]  Yoshiaki Kawase,et al.  Rescuing the failing heart by targeted gene transfer. , 2011, Journal of the American College of Cardiology.

[122]  Vladimir I Martynov,et al.  GFP family: structural insights into spectral tuning. , 2008, Chemistry & biology.

[123]  U. Schmidt,et al.  Increased leakage of sarcoplasmic reticulum Ca2+ contributes to abnormal myocyte Ca2+ handling and shortening in sepsis* , 2005, Critical care medicine.

[124]  R. Hajjar,et al.  Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. , 2011, The Journal of clinical investigation.

[125]  H. Sweeney,et al.  Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines. , 2011, Human gene therapy.

[126]  R. Bobe,et al.  How many Ca2+ATPase isoforms are expressed in a cell type? A growing family of membrane proteins illustrated by studies in platelets , 2005, Platelets.

[127]  I. V. Negrashov,et al.  SERCA structural dynamics induced by ATP and calcium. , 2004, Biochemistry.

[128]  D. Bernlohr,et al.  Protein carbonylation and metabolic control systems , 2012, Trends in Endocrinology & Metabolism.

[129]  M. Futai,et al.  Proton pumping ATPases and diverse inside-acidic compartments. , 2004, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[130]  G. Marazzi,et al.  Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship. , 2008, Journal of medicinal chemistry.

[131]  A. Zima,et al.  Phospholamban Binds with Differential Affinity to Calcium Pump Conformers* , 2011, The Journal of Biological Chemistry.

[132]  D. Mancini,et al.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. , 2009, Journal of cardiac failure.

[133]  David D. Thomas,et al.  Atomic-Level Characterization of the Activation Mechanism of SERCA by Calcium , 2011, PloS one.

[134]  E. Ariazi,et al.  Estrogen-related receptors as emerging targets in cancer and metabolic disorders. , 2006, Current topics in medicinal chemistry.

[135]  A. Hovnanian,et al.  Dissection of the Functional Differences between Sarco(endo)plasmic Reticulum Ca2+-ATPase (SERCA) 1 and 2 Isoforms and Characterization of Darier Disease (SERCA2) Mutants by Steady-state and Transient Kinetic Analyses* , 2003, Journal of Biological Chemistry.

[136]  J. Andersen,et al.  Amino acids Asn796 and Thr799 of the Ca(2+)-ATPase of sarcoplasmic reticulum bind Ca2+ at different sites. , 1994, The Journal of biological chemistry.

[137]  David D. Thomas,et al.  Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure. , 2011, Biochemical and biophysical research communications.

[138]  L. Jones,et al.  Mechanism of Reversal of Phospholamban Inhibition of the Cardiac Ca2+-ATPase by Protein Kinase A and by Anti-phospholamban Monoclonal Antibody 2D12* , 2007, Journal of Biological Chemistry.

[139]  S. Opella,et al.  Bicelle samples for solid-state NMR of membrane proteins , 2007, Nature Protocols.

[140]  Lee H. Dicker,et al.  Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity , 2011, Nature.

[141]  J. García-Sancho,et al.  Two distinct calcium pools in the endoplasmic reticulum of HEK-293T cells. , 2011, The Biochemical journal.

[142]  H. Orr.  SCA1—Phosphorylation, a regulator of Ataxin-1 function and pathogenesis , 2012, Progress in Neurobiology.

[143]  C. Toyoshima,et al.  Interaction sites among phospholamban, sarcolipin, and the sarco(endo)plasmic reticulum Ca(2+)-ATPase. , 2008, Biochemical and biophysical research communications.

[144]  P. Vangheluwe,et al.  The Ca2+ pumps of the endoplasmic reticulum and Golgi apparatus. , 2011, Cold Spring Harbor perspectives in biology.

[145]  G. Fan,et al.  A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids , 2008, Human mutation.

[146]  G. Strasburg,et al.  Differential Ca(2+) sensitivity of skeletal and cardiac muscle ryanodine receptors in the presence of calmodulin. , 2000, American journal of physiology. Cell physiology.

[147]  David D. Thomas,et al.  Lipid-mediated folding/unfolding of phospholamban as a regulatory mechanism for the sarcoplasmic reticulum Ca2+-ATPase. , 2011, Journal of molecular biology.

[148]  H. Ly,et al.  Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. , 2008, Journal of the American College of Cardiology.

[149]  E. Kranias,et al.  Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.

[150]  C. Holmes,et al.  Lethal, Hereditary Mutants of Phospholamban Elude Phosphorylation by Protein Kinase A* , 2012, The Journal of Biological Chemistry.

[151]  V. Erdmann,et al.  Long-Term Cardiac-Targeted RNA Interference for the Treatment of Heart Failure Restores Cardiac Function and Reduces Pathological Hypertrophy , 2009, Circulation.

[152]  D. Stokes,et al.  Phosphorylation and mutation of phospholamban alter physical interactions with the sarcoplasmic reticulum calcium pump. , 2011, Journal of molecular biology.

[153]  N. Green,et al.  Site-directed Disulfide Mapping of Helices M4 and M6 in the Ca2+ Binding Domain of SERCA1a, the Ca2+ ATPase of Fast Twitch Skeletal Muscle Sarcoplasmic Reticulum* , 1997, The Journal of Biological Chemistry.

[154]  D. Maclennan.  Purification and properties of an adenosine triphosphatase from sarcoplasmic reticulum. , 1970, The Journal of biological chemistry.

[155]  E. White,et al.  Co-ordinated changes in cAMP, phosphorylated phospholamban, Ca2+ and contraction following β-adrenergic stimulation of rat heart , 1998, Pflügers Archiv.

[156]  A. de Haan,et al.  Calcium regulation and muscle disease , 2004, Journal of Muscle Research & Cell Motility.

[157]  D. Stokes,et al.  Role of Leucine 31 of Phospholamban in Structural and Functional Interactions with the Ca2+ Pump of Cardiac Sarcoplasmic Reticulum* , 2005, Journal of Biological Chemistry.

[158]  J. Guerrero,et al.  Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[159]  David D. Thomas,et al.  2-Color Calcium Pump Reveals Closure of the Cytoplasmic Headpiece with Calcium Binding , 2012, PloS one.

[160]  L. Jones,et al.  Functional Co-expression of the Canine Cardiac Ca2+Pump and Phospholamban in Spodoptera frugiperda (Sf21) Cells Reveals New Insights on ATPase Regulation* , 1997, The Journal of Biological Chemistry.

[161]  David D. Thomas,et al.  Accurate quantitation of phospholamban phosphorylation by immunoblot. , 2012, Analytical biochemistry.

[162]  Yoshiaki Kawase,et al.  Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. , 2008, Journal of cardiac failure.

[163]  Barry Greenberg,et al.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A Phase 2 Trial of Intracoronary Gene Therapy of Sarcoplasmic Reticulum Ca2+-ATPase in Patients With Advanced Heart Failure , 2011, Circulation.

[164]  A. Mansur,et al.  Mutations in the human phospholamban gene in patients with heart failure. , 2011, American heart journal.